J&J resumes roll-out of COVID-19 vaccine in EU

J&J resumes roll-out of COVID-19 vaccine in EU
21st April 2021
Johnson & Johnson (J&J) is planning to resume the roll-out of its COVID-19 vaccine in the EU following updated guidance from the European Medicines Agency’s (EMA) safety committee.
The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has reviewed a small number of cases of very rare blood clots in combination with low platelet counts in individuals who have received the J&J vaccine.
According to J&J, these very rare adverse events can occur within approximately one to three weeks following injection with its COVID-19 vaccine.
The PRAC has confirmed the overall benefit-risk profile of J&J’s COVID-19 vaccine, although J&J must update the product information for the jab to include information on the diagnosis and management of this type of rare adverse event.

Related Keywords

Norway ,Iceland ,Paul Stoffels ,Johnson ,Centers For Disease ,Pharmacovigilance Risk Assessment Committee ,European Union ,European Medicines Agency ,Drug Administration ,Advisory Committee On Immunisation Practices ,Risk Assessment Committee ,Healthcare Professionals ,Disease Control ,Immunisation Practices , ,நோர்வே ,ஐஸ்லாந்து ,ஜான்சன் ,மையங்கள் க்கு நோய் ,மருந்தியல் ஆபத்து மதிப்பீடு குழு ,ஐரோப்பிய தொழிற்சங்கம் ,ஆபத்து மதிப்பீடு குழு ,சுகாதாரம் ப்ரொஃபெஶநல்ஸ் ,நோய் கட்டுப்பாடு ,நோய்த்தடுப்பு ப்ர்யாக்டிஸஸ் ,